ijms-logo

Journal Browser

Journal Browser

Peptide Hormones in Human Diseases and Health

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Endocrinology and Metabolism".

Deadline for manuscript submissions: 28 August 2024 | Viewed by 3036

Special Issue Editor


E-Mail Website
Guest Editor
Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, BC V6T 1Z3, Canada
Interests: cancer biology; neurogenerative diseases; aging; BBB; diabetes; peptide processing; G-protein coupled receptors
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Peptide hormones have been shown to be involved in almost all physiological cell responses in central and peripheral tissues. Furthermore, changes in the sysnthesis and release of peptide hormones from target tissues are associated with a wide range of pathological conditions. Growing evidence supports the synthesis of the peptide hormone-based design of drugs as an effective therapeutic alternative in many diseases. Proposed mechanisms are multifactorial and hormone peptides that work through corresponding receptor proteins with an ability to control energy homeostasis and metabolisn and modulate the downstream signaling pathways and physiological responses of cells, thus emerging as an effective drugs in many central and peripheral diseases. IJMS has been very successful in organizing multiple Special Issues in different areas of research and is pleased to announce a special issue on peptide hormones in human disease and health. We believe that this Special Issue will bring new information about peptide hormones targeting therapeutic intervention in many disease conditions. Here, we invite manuscripts or review articles for submission to a Special Issue on “Peptide Hormones in Human Diseases and Health” from the International Journal of Molecular Sciences (IJMS) with an impact factor of 5.6.

Dr. Ujendra Kumar
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • central nervous syetem
  • hormone
  • neuropeptide
  • peptide
  • receptors
  • signaling pathways
  • peripheral system

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

18 pages, 2811 KiB  
Article
GnRH Induces Citrullination of the Cytoskeleton in Murine Gonadotrope Cells
by Elizabeth B. Quigley, Stanley B. DeVore, Shaihla A. Khan, Zachary M. Geisterfer, Heather M. Rothfuss, Ari O. Sequoia, Paul R. Thompson, Jesse C. Gatlin, Brian D. Cherrington and Amy M. Navratil
Int. J. Mol. Sci. 2024, 25(6), 3181; https://doi.org/10.3390/ijms25063181 - 10 Mar 2024
Viewed by 697
Abstract
Peptidylarginine deiminases (PADs or PADIs) catalyze the conversion of positively charged arginine to neutral citrulline, which alters target protein structure and function. Our previous work established that gonadotropin-releasing hormone agonist (GnRHa) stimulates PAD2-catalyzed histone citrullination to epigenetically regulate gonadotropin gene expression in the [...] Read more.
Peptidylarginine deiminases (PADs or PADIs) catalyze the conversion of positively charged arginine to neutral citrulline, which alters target protein structure and function. Our previous work established that gonadotropin-releasing hormone agonist (GnRHa) stimulates PAD2-catalyzed histone citrullination to epigenetically regulate gonadotropin gene expression in the gonadotrope-derived LβT2 cell line. However, PADs are also found in the cytoplasm. Given this, we used mass spectrometry (MS) to identify additional non-histone proteins that are citrullinated following GnRHa stimulation and characterized the temporal dynamics of this modification. Our results show that actin and tubulin are citrullinated, which led us to hypothesize that GnRHa might induce their citrullination to modulate cytoskeletal dynamics and architecture. The data show that 10 nM GnRHa induces the citrullination of β-actin, with elevated levels occurring at 10 min. The level of β-actin citrullination is reduced in the presence of the pan-PAD inhibitor biphenyl-benzimidazole-Cl-amidine (BB-ClA), which also prevents GnRHa-induced actin reorganization in dispersed murine gonadotrope cells. GnRHa induces the citrullination of β-tubulin, with elevated levels occurring at 30 min, and this response is attenuated in the presence of PAD inhibition. To examine the functional consequence of β-tubulin citrullination, we utilized fluorescently tagged end binding protein 1 (EB1-GFP) to track the growing plus end of microtubules (MT) in real time in transfected LβT2 cells. Time-lapse confocal microscopy of EB1-GFP reveals that the MT average lifetime increases following 30 min of GnRHa treatment, but this increase is attenuated by PAD inhibition. Taken together, our data suggest that GnRHa-induced citrullination alters actin reorganization and MT lifetime in gonadotrope cells. Full article
(This article belongs to the Special Issue Peptide Hormones in Human Diseases and Health)
Show Figures

Figure 1

Review

Jump to: Research

61 pages, 3318 KiB  
Review
Somatostatin and Somatostatin Receptors in Tumour Biology
by Ujendra Kumar
Int. J. Mol. Sci. 2024, 25(1), 436; https://doi.org/10.3390/ijms25010436 - 28 Dec 2023
Cited by 2 | Viewed by 1871
Abstract
Somatostatin (SST), a growth hormone inhibitory peptide, is expressed in endocrine and non-endocrine tissues, immune cells and the central nervous system (CNS). Post-release from secretory or immune cells, the first most appreciated role that SST exhibits is the antiproliferative effect in target tissue [...] Read more.
Somatostatin (SST), a growth hormone inhibitory peptide, is expressed in endocrine and non-endocrine tissues, immune cells and the central nervous system (CNS). Post-release from secretory or immune cells, the first most appreciated role that SST exhibits is the antiproliferative effect in target tissue that served as a potential therapeutic intervention in various tumours of different origins. The SST-mediated in vivo and/or in vitro antiproliferative effect in the tumour is considered direct via activation of five different somatostatin receptor subtypes (SSTR1-5), which are well expressed in most tumours and often more than one receptor in a single cell. Second, the indirect effect is associated with the regulation of growth factors. SSTR subtypes are crucial in tumour diagnosis and prognosis. In this review, with the recent development of new SST analogues and receptor-specific agonists with emerging functional consequences of signaling pathways are promising therapeutic avenues in tumours of different origins that are discussed. Full article
(This article belongs to the Special Issue Peptide Hormones in Human Diseases and Health)
Show Figures

Figure 1

Back to TopTop